+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Colorectal Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Colorectal Cancer Drugs Market - Global Forecast 2026-2032- Product Image
New

Colorectal Cancer Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896776
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Colorectal Cancer Drugs Market is undergoing significant transformation, shaped by advancements in targeted treatments, regulatory adaptation, and new approaches to care delivery. Senior decision-makers face a complex environment where clinical innovation and operational resilience increasingly define competitive advantage.

Market Snapshot: Colorectal Cancer Drugs Market Overview

The global Colorectal Cancer Drugs Market recorded substantial growth, rising from USD 11.99 billion in 2025 to USD 12.66 billion in 2026. With a compound annual growth rate (CAGR) of 7.24%, projections indicate the market will reach USD 19.57 billion by 2032. This expansion is propelled by continuous demand for immuno-oncology innovations, emerging targeted therapies, and diversified distribution strategies. The evolving landscape supports opportunities for both established leaders and new entrants striving for market relevance, as companies adapt to the integration of novel treatments and expanded access models.

Scope & Segmentation: Assessing the Evolving Therapeutic Landscape

  • Drug Classes: Encompasses cytotoxic chemotherapies, immuno-oncology agents, monoclonal antibodies targeting EGFR and VEGF, as well as small molecule inhibitors focused on BRAF, MEK, and tyrosine kinases.
  • Administration Routes: Includes intravenous, oral, and subcutaneous formats, reflecting the growing need for outpatient-capable therapies that enhance patient adherence and accessibility.
  • Distribution Channels: Considers hospital pharmacies, retail pharmacies, and online platforms, each supporting distinct care settings affecting market access and reach.
  • Therapeutic Lines & Molecular Targets: Covers first-line and subsequent treatment strategies, with attention to personalized regimens aimed at EGFR, PD-1/PD-L1 pathways, and resistance management.
  • Care Settings: Highlights the unique dynamics of inpatient, outpatient, and chronic management environments, acknowledging their influence on reimbursement patterns and operational priorities.
  • Regional Markets: Addresses leading geographies, including the Americas, Europe, Middle East & Africa, and Asia-Pacific, each marked by distinctive regulatory conditions, reimbursement mechanisms, and local innovation capacity.
  • Technologies: Reviews companion diagnostics, real-world evidence platforms, and digital patient support tools, which facilitate precise therapy alignment and enhanced monitoring for better patient outcomes.

Key Takeaways: Strategic Insights for Decision-Makers

  • Precision diagnostics and biomarker-driven patient selection are shifting therapy choices and fostering more informed payer negotiations in the colorectal cancer drugs segment.
  • Rising emphasis on outpatient and self-administrable formulations, such as oral and subcutaneous drugs, is lowering resource demands and improving reach for decentralized care models.
  • Flexible manufacturing capabilities and multi-source procurement strategies are critical for maintaining steady supply amidst changing global trade conditions.
  • Regulatory pathways that accelerate trial design and evidence submission are increasing, placing new importance on diagnostics-therapeutics integration and agile evidence-generation approaches.
  • Collaborative alliances—including research, development, and manufacturing—are pivotal for overcoming reimbursement barriers, facilitating local entry, and speeding market access.
  • Younger and mid-sized firms are gaining ground by targeting specialized indications, leveraging digital innovation, and focusing on strategic partnerships rather than scaling manufacturing operations.

Tariff Impact: Navigating Trade Policy and Operational Risks

Recent United States tariff and trade policy shifts have influenced sourcing, procurement, and production strategies for oncology therapeutics. Companies are reassessing supplier networks, making investments in localized manufacturing, and broadening sourcing across multiple regions for active pharmaceutical ingredients. Contract renegotiations with distributors and new delivery timelines are helping organizations reduce tariff exposure and ensure business continuity. This evolving trade environment further underscores the need for adaptability and contingency planning within global supply chains.

Methodology & Data Sources

This research utilizes an integrated approach, drawing on expert interviews with leaders in clinical, regulatory, and supply chain roles. Quantitative insights are validated through regulatory filings, clinical trial data, and public records. Each data point is methodically triangulated to ensure present-day accuracy, and any areas with potential data lag or misalignment with emerging trends are transparently noted.

Why This Report Matters: Actionable Guidance for Senior Leadership

  • Supplies executives with a strategic view on aligning scientific progress, resilient operations, and payer expectations for success in the colorectal cancer drugs market.
  • Provides segmentation and regional analysis to guide investment strategy, portfolio development, and partnership pursuits.
  • Delivers intelligence that helps mitigate operational risk, inform regulatory adaptation, and optimize care delivery across decentralized settings.

Conclusion: Strategic Synthesis

Leadership in the colorectal cancer drugs sector hinges on harmonizing precision medicine, supply chain strength, and payer engagement. Staying agile amid evolving trends and operating environments is essential for sustaining competitive positioning.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Colorectal Cancer Drugs Market, by Drug Class
8.1. Chemotherapy
8.1.1. Fluoropyrimidines
8.1.2. Platinum Compounds
8.1.3. Topoisomerase Inhibitors
8.2. Immunotherapy
8.2.1. Adoptive Cell Therapies
8.2.2. Checkpoint Inhibitors
8.3. Monoclonal Antibodies
8.3.1. Epidermal Growth Factor Receptor Inhibitors
8.3.2. Vascular Endothelial Growth Factor Inhibitors
8.4. Small Molecule Inhibitors
8.4.1. BRAF Inhibitors
8.4.2. MEK Inhibitors
8.4.3. Tyrosine Kinase Inhibitors
9. Colorectal Cancer Drugs Market, by Distribution Channel
9.1. Hospital Pharmacies
9.2. Online Pharmacies
9.3. Retail Pharmacies
10. Colorectal Cancer Drugs Market, by Route Of Administration
10.1. Intravenous
10.2. Oral
10.3. Subcutaneous
11. Colorectal Cancer Drugs Market, by Line Of Therapy
11.1. First Line
11.2. Second Line
11.3. Third Line
12. Colorectal Cancer Drugs Market, by Target Molecule
12.1. Epidermal Growth Factor Receptor
12.2. Programmed Cell Death Protein 1
12.3. Programmed Death Ligand 1
12.4. Vascular Endothelial Growth Factor
13. Colorectal Cancer Drugs Market, by Treatment Setting
13.1. Inpatient
13.2. Outpatient
14. Colorectal Cancer Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Colorectal Cancer Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Colorectal Cancer Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Colorectal Cancer Drugs Market
18. China Colorectal Cancer Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
19.6. Amgen Inc.
19.7. Amneal Pharmaceuticals, Inc.
19.8. Apotex Inc.
19.9. Bayer AG
19.10. Bristol-Myers Squibb Company
19.11. Eisai Co., Ltd.
19.12. Eli Lilly and Company
19.13. F. Hoffmann-La Roche Ltd
19.14. GlaxoSmithKline PLC
19.15. HUTCHMED (China) Limited
19.16. Lupin Limited
19.17. Mallinckrodt Pharmaceuticals
19.18. Manus Aktteva Biopharma LLP
19.19. Marksans Pharma Ltd.
19.20. Merck & Co., Inc.
19.21. Mylan N.V. by Viatris Inc.
19.22. Novartis AG
19.23. Pfizer Inc.
19.24. Regeneron Pharmaceuticals, Inc.
19.25. Sanofi S.A.
19.26. Sumitomo Pharma Co., Ltd.
19.27. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
19.28. Takeda Pharmaceutical Company Limited
19.29. VolitionRx Limited
List of Figures
FIGURE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 144. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 147. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 149. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 153. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 154. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 166. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 169. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 170. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 171. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 175. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 176. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 192. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 194. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 198. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 199. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 200. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 202. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 203. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 204. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 205. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 206. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 209. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 210. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 222. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 225. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 226. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 227. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 228. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 230. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 231. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 232. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 233. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 236. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 237. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 238. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 239. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 242. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 243. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 244. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 246. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 247. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 248. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 249. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 250. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 252. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 253. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 254. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 267. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 269. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 270. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 271. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 272. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 273. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 274. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 275. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 276. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
TABLE 277. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Colorectal Cancer Drugs market report include:
  • Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • HUTCHMED (China) Limited
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Marksans Pharma Ltd.
  • Merck & Co., Inc.
  • Mylan N.V. by Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VolitionRx Limited

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 12.66 Billion
Forecasted Market Value ( USD ) by 2032 $ 19.57 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Colorectal Cancer Drugs Market Report 2025 - Product Image

Colorectal Cancer Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Metastatic Colorectal Cancer Drugs - Global Strategic Business Report - Product Image

Metastatic Colorectal Cancer Drugs - Global Strategic Business Report

  • Report
  • 626 Pages
  • Global
From
Colorectal Cancer Drugs Global Market Opportunities and Strategies to 2034 - Product Image

Colorectal Cancer Drugs Global Market Opportunities and Strategies to 2034

  • Report
  • 337 Pages
  • Global
From
Colorectal Cancer Drug Pipeline Analysis Report 2025 - Product Image

Colorectal Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Colorectal Cancer Drug Market

The Colorectal Cancer Drug market is composed of drugs used to treat colon cancer. These drugs are used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include chemotherapy, targeted therapy, immunotherapy, and hormone therapy. Chemotherapy is the most common treatment for colon cancer, and is used to kill cancer cells. Targeted therapy is used to target specific molecules in cancer cells, while immunotherapy is used to boost the body’s immune system to fight cancer. Hormone therapy is used to reduce the production of hormones that can cause cancer cells to grow. Companies in the Colorectal Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.